Patents by Inventor Chi-Ling Tseng
Chi-Ling Tseng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240083960Abstract: This disclosure relates to engineered SIRP? variants, and methods of use thereof.Type: ApplicationFiled: October 31, 2023Publication date: March 14, 2024Inventors: Jiin-Tarng Wang, Han-Fang Teng, Pan-Hsien Kuo, Chi-Ling Tseng, Zong Sean Juo
-
Publication number: 20230340098Abstract: Provided are antibodies and antibody derivatives that bind to GARP (also known as LRRC32 and CPPRDD) and/or GARP/TGF? complexand methods of using the same. In certain embodiments, an anti-GARP/TGF? antibody or antibody derivative provided herein can inhibit a TGF? signal pathway in a target cell.Type: ApplicationFiled: May 31, 2023Publication date: October 26, 2023Applicant: SHANGHAI HENLIUS BIOTECH, INC.Inventors: Jiin-Tarng WANG, Chi-Ling TSENG, Wei-Dong JIANG, Bin CHEN, Yao XU, Jie GAO
-
Publication number: 20230279110Abstract: The present disclosure relates to antibodies and antibody derivatives that bind to CD47 (also known as IAP, MER6 and OA3) and methods of using the same. In certain embodiments, an anti-CD47 antibody or antibody derivative disclosed herein exhibits reduced binding to a red blood cell.Type: ApplicationFiled: March 24, 2023Publication date: September 7, 2023Inventors: Jiin-Tarng WANG, Chi-Ling TSENG, Wei-Dong JIANG
-
Patent number: 11685783Abstract: Provided are anti-PD-1 antibodies, and antigen binding fragments thereof. Also provided are isolated nucleic acid molecules that encode the anti-PD-1 antibodies or antigen binding fragments thereof, related expression vectors, and host cells. Provided are methods of making anti-PD-1 antibodies, and antigen binding fragments thereof. Also provided are related pharmaceutical compositions and methods of their use to treat subjects. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.Type: GrantFiled: April 29, 2021Date of Patent: June 27, 2023Assignee: Shanghai Henlius Biotech Inc.Inventors: Weidong Jiang, Pei-Hua Lin, Chi-Ling Tseng
-
Patent number: 11618786Abstract: Provided are anti-PD-L1 antibodies, variants, mutants, and antigen binding fragments thereof. Also provided are isolated nucleic acid molecules that encode the anti-PD-L1 antibodies, variants, mutants, or antigen binding fragments thereof, and related expression vectors, and host cells. Provided are methods of making anti-PD-L1 antibodies, variants, mutants, and antigen binding fragments thereof. Also provided are related pharmaceutical compositions and methods of their use to treat subjects. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.Type: GrantFiled: January 25, 2022Date of Patent: April 4, 2023Assignee: Shanghai Henlius Biotech Inc.Inventors: Weidong Jiang, Pei-Hua Lin, Chi-Ling Tseng
-
Publication number: 20220162334Abstract: Provided are anti-CD73 antibodies, variants, and antigen binding fragments thereof. The antibodies, the variants, and the antigen binding fragments thereof bind to human CD73 with high affinity, and suppress the enzymatic activity of CD73, and optionally induce CD73 internalization. Further provided are isolated nucleic acid molecules encoding the anti-CD73 antibodies, the variants, and the antigen binding fragments thereof, and a related expression vector and a host cell. Provided is a method for preparing the anti-CD73 antibodies, the variants, and the antigen binding fragments thereof. Further provided are related pharmaceutical compositions and a method for using said pharmaceutical compositions in treating a subject.Type: ApplicationFiled: January 25, 2022Publication date: May 26, 2022Inventors: Wei-Dong JIANG, I-yin CHEN, Chi-Ling TSENG
-
Publication number: 20220144955Abstract: Provided are anti-PD-L1 antibodies, variants, mutants, and antigen binding fragments thereof. Also provided are isolated nucleic acid molecules that encode the anti-PD-L1 antibodies, variants, mutants, or antigen binding fragments thereof, and related expression vectors, and host cells. Provided are methods of making anti-PD-L1 antibodies, variants, mutants, and antigen binding fragments thereof. Also provided are related pharmaceutical compositions and methods of their use to treat subjects. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.Type: ApplicationFiled: January 25, 2022Publication date: May 12, 2022Applicant: Shanghai Henlius Biotech Inc.Inventors: Weidong JIANG, Pei-Hua LIN, Chi-Ling Tseng
-
Patent number: 11274155Abstract: Provided are anti-PD-L1 antibodies, variants, mutants, and antigen binding fragments thereof. Also provided are isolated nucleic acid molecules that encode the anti-PD-L1 antibodies, variants, mutants, or antigen binding fragments thereof, and related expression vectors, and host cells. Provided are methods of making anti-PD-L1 antibodies, variants, mutants, and antigen binding fragments thereof. Also provided are related pharmaceutical compositions and methods of their use to treat subjects. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.Type: GrantFiled: April 10, 2019Date of Patent: March 15, 2022Assignee: Shanghai Henlius Biotech Inc.Inventors: Weidong Jiang, Pei-Hua Lin, Chi-Ling Tseng
-
Publication number: 20210277122Abstract: Provided are anti-PD-1 antibodies, and antigen binding fragments thereof. Also provided are isolated nucleic acid molecules that encode the anti-PD-1 antibodies or antigen binding fragments thereof, related expression vectors, and host cells. Provided are methods of making anti-PD-1 antibodies, and antigen binding fragments thereof. Also provided are related pharmaceutical compositions and methods of their use to treat subjects. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.Type: ApplicationFiled: April 29, 2021Publication date: September 9, 2021Applicant: Shanghai Henlius Biotech Inc.Inventors: Weidong JIANG, Pei-Hua LIN, Chi-Ling Tseng
-
Patent number: 11028173Abstract: Provided are anti-PD-1 antibodies, and antigen binding fragments thereof. Also provided are isolated nucleic acid molecules that encode the anti-PD-1 antibodies or antigen binding fragments thereof, related expression vectors, and host cells. Provided are methods of making anti-PD-1 antibodies, and antigen binding fragments thereof. Also provided are related pharmaceutical compositions and methods of their use to treat subjects. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.Type: GrantFiled: March 13, 2019Date of Patent: June 8, 2021Assignee: Shanghai Henlius Biotech, Inc.Inventors: Weidong Jiang, Pei-Hua Lin, Chi-Ling Tseng
-
Publication number: 20190225691Abstract: Provided are anti-PD-L1 antibodies, variants, mutants, and antigen binding fragments thereof. Also provided are isolated nucleic acid molecules that encode the anti-PD-L1 antibodies, variants, mutants, or antigen binding fragments thereof, and related expression vectors, and host cells. Provided are methods of making anti-PD-L1 antibodies, variants, mutants, and antigen binding fragments thereof. Also provided are related pharmaceutical compositions and methods of their use to treat subjects. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.Type: ApplicationFiled: April 10, 2019Publication date: July 25, 2019Applicant: Shanghai Henlius Biotech Inc.Inventors: Weidong JIANG, Pei-Hua LIN, Chi-Ling TSENG
-
Publication number: 20190218295Abstract: Provided are anti-PD-1 antibodies, and antigen binding fragments thereof. Also provided are isolated nucleic acid molecules that encode the anti-PD-1 antibodies or antigen binding fragments thereof, related expression vectors, and host cells. Provided are methods of making anti-PD-1 antibodies, and antigen binding fragments thereof. Also provided are related pharmaceutical compositions and methods of their use to treat subjects. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.Type: ApplicationFiled: March 13, 2019Publication date: July 18, 2019Applicant: Shanghai Henlius Biotech Inc.Inventors: Weidong Jiang, Pei-Hua Lin, Chi-Ling Tseng
-
Publication number: 20180193456Abstract: Provided are anti-vascular endothelial growth factor receptor 2 (VEGFR2) antibodies, and antigen binding fragments thereof. Also provided are isolated nucleic acid molecules that encode the anti-VEGFR2 antibodies or antigen binding fragments thereof, related expression vectors, and host cells. Provided are methods of making anti-VEGFR2 antibodies and antigen binding fragments thereof. Also provided are related pharmaceutical compositions comprising anti-VEGFR2 antibodies (or antigen binding fragments thereof) and methods of their use in the treatment of pathological conditions characterized by excessive angiogenesis.Type: ApplicationFiled: June 29, 2016Publication date: July 12, 2018Inventors: Wei-Dong JIANG, Pei-Hua LIN, Chi-Ling TSENG
-
Patent number: 8771990Abstract: A method of producing a recombinant lipidated polypeptide in E. coli. The method includes providing an E. coli host cell adapted to express a recombinant lipidated polypeptide; and culturing the E. coli host cell in a minimal medium under conditions that allow expression of the polypeptide in lipidated form.Type: GrantFiled: November 15, 2011Date of Patent: July 8, 2014Assignee: National Health Research InstitutesInventors: Chih-Hsiang Leng, Chi-Ling Tseng, Shih-Jen Liu, Hsin-Wei Chen, Pele Choi-Sing Chong
-
Patent number: 8658767Abstract: This invention relates to, inter alia, an isolated lipidated polypeptide including a lipid moiety at the N-terminus and a plurality of epitopes, and methods of making and using the polypeptide.Type: GrantFiled: November 15, 2011Date of Patent: February 25, 2014Assignee: National Health Research InstitutesInventors: Chih-Hsiang Leng, Chi-Ling Tseng, Hsueh-Hung Liu, Shih-Jen Liu, Hsin-Wei Chen, Pele Choi-Sing Chong
-
Publication number: 20120122154Abstract: A method of producing a recombinant lipidated polypeptide in E. coli. The method includes providing an E. coli host cell adapted to express a recombinant lipidated polypeptide; and culturing the E. coli host cell in a minimal medium under conditions that allow expression of the polypeptide in lipidated form.Type: ApplicationFiled: November 15, 2011Publication date: May 17, 2012Applicant: National Health Research InstitutesInventors: Chih-Hsiang Leng, Chi-Ling Tseng, Shih-Jen Liu, Hsin-Wei Chen, Pele Choi-Sing Chong
-
Publication number: 20120121628Abstract: This invention relates to, inter alia, an isolated lipidated polypeptide including a lipid moiety at the N-terminus and a plurality of epitopes, and methods of making and using the polypeptide.Type: ApplicationFiled: November 15, 2011Publication date: May 17, 2012Applicant: National Health Research InstitutesInventors: Chih-Hsiang Leng, Chi-Ling Tseng, Hsueh-Hung Liu, Shih-Jen Liu, Hsin-Wei Chen, Pele Choi-Sing Chong